Sunday, June 21, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,771
Drugs linked 4,798

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 762 of 1,261

  1. US 8987420

    High affinity human antibodies to human angiopoietin-2

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 24, 2015 · Expires Mar 19, 2035

    granted

  2. US 8987454

    Azaindoles useful as inhibitors of JAK and other protein kinases

    Vertex Pharmaceuticals Incorporated · Granted Mar 24, 2015 · Expires Mar 19, 2035

    granted

  3. US 8987303

    AMPK-activating heterocyclic compounds and methods for using the same

    Rigel Pharmaceuticals, Inc. · Granted Mar 24, 2015 · Expires Mar 19, 2035

    granted

  4. US 8986653

    Labeled iodinated tropane formulation

    Alseres Pharmaceuticals, Inc. · Granted Mar 24, 2015 · Expires Mar 19, 2035

    granted

  5. US 8986695

    Enhanced staphylolytic activity of the Staphylococcus aureus bacteriophage vB—SauS-philPLA88 virion-associated peptidoglycan hydrolase HydH5: fusions, deletions and synergy with LysH5

    The United States of America, as represented by the Secretary of Agriculture · Granted Mar 24, 2015 · Expires Mar 19, 2035

    granted

  6. WO 2015036507

    UTILISATION DE CABAZITAXEL CHEZ DES PATIENTS CHEZ QUI UN CANCER DU POUMON NON À PETITES CELLULES MÉTASTATIQUE CONTINUE À PROGRESSER APRÈS UN TRAITEMENT À BASE DE DOCÉTAXEL

    AVENTIS PHARMA SA [FR] · Granted Mar 19, 2015 · Expires Mar 14, 2035

    granted

  7. EP 2846808

    ZUCKERZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON HÄMOPHILIE A UND/ODER VON-WILLEBRAND-SYNDROM

    CSL BEHRING GMBH [DE] · Granted Mar 18, 2015 · Expires Mar 13, 2035

    granted

  8. EP 2847225

    ANTIKÖRPER GEGEN CLAUDIN 18.2 FÜR DIE KREBSDIAGNOSE

    GANYMED PHARMACEUTICALS AG [DE] · Granted Mar 18, 2015 · Expires Mar 13, 2035

    granted

  9. US 8980859

    Aegyptin and uses thereof

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Mar 17, 2015 · Expires Mar 12, 2035

    granted

  10. US 8980275

    Targeted heterologous antigen presentation on calicivirus virus-like particles

    Takeda Vaccines, Inc. · Granted Mar 17, 2015 · Expires Mar 12, 2035

    granted

  11. US 8980322

    Controlled release composition

    Takeda Pharmaceutical Company Limited · Granted Mar 17, 2015 · Expires Mar 12, 2035

    granted

  12. US 8980838

    Cyclized peptidomimetic small molecule inhibitors of the WDR5 and MLL1 interaction

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Mar 17, 2015 · Expires Mar 12, 2035

    granted

  13. US 8980921

    AMPK-activating heterocyclic compounds and methods for using the same

    Rigel Pharmaceuticals, Inc. · Granted Mar 17, 2015 · Expires Mar 12, 2035

    granted

  14. US 8980902

    Poly (ADP-ribose) polymerase (PARP) inhibitors

    Takeda Pharmaceutical Company Limited · Granted Mar 17, 2015 · Expires Mar 12, 2035

    granted

  15. US 8980343

    Plant extract, compositions containing same, method of extraction and uses thereof

    Botanic Century (Beijing) Co. Ltd. · Granted Mar 17, 2015 · Expires Mar 12, 2035

    granted

  16. US 8980258

    Bispecific single chain Fv antibody molecules and methods of use therof

    The Regents of the University of California · Granted Mar 17, 2015 · Expires Mar 12, 2035

    granted

  17. US 8980883

    Arylpiperazine derivatives and methods of utilizing same

    REVIVA PHARMACEUTICALS, INC. · Granted Mar 17, 2015 · Expires Mar 12, 2035

    granted

  18. US 8980871

    Methods of treatment for hemolysis

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Mar 17, 2015 · Expires Mar 12, 2035

    granted

  19. US 8981046

    Synthetic cell platforms and methods of use thereof

    The Regents of the University of California · Granted Mar 17, 2015 · Expires Mar 12, 2035

    granted

  20. US 8980855

    Minor groove binder (MGB)-oligonucleotide miRNA antagonists

    Elitech Holding B.V. · Granted Mar 17, 2015 · Expires Mar 12, 2035

    granted

  21. US 8980887

    2-aryl imidazo[1,2-a]pyridine-3-acetamide derivatives, preparation methods and uses thereof

    Toxicology Academy of Military Medical Sciences P.L.A., China · Granted Mar 17, 2015 · Expires Mar 12, 2035

    granted

  22. US 8980899

    Methods of inhibiting Ire1

    The Regents of the University of California · Granted Mar 17, 2015 · Expires Mar 12, 2035

    granted

  23. US 8980608

    High molecular weight heparosan polymers and methods of production and use thereof

    The Board of Regents of the University of Oklahoma · Granted Mar 17, 2015 · Expires Mar 12, 2035

    granted

  24. US 8980549

    MicroRNA patterns for the diagnosis, prognosis and treatment of melanoma

    TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD. · Granted Mar 17, 2015 · Expires Mar 12, 2035

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.